"This may be a way of treating earlier stage aggressive prostate cancer with chemotherapy and selecting patients based upon their biological profiles," says Daniel P. Petrylak, MD.
In this video, Daniel P. Petrylak, MD, discusses the ongoing phase 2 SWOG S2210 trial (NCT05806515) of neoadjuvant carboplatin in patients with localized, high-risk prostate cancer and germline BRCA1/2 mutations. Petrylak is professor of medicine (medical oncology) and of urology at Yale School of Medicine and chief of genitourinary oncology at Yale Cancer Center, New Haven, Connecticut.
Could you describe the design and key end points for this study?
The study is designed to evaluate high-risk patients. These patients have T3 or T4 disease, a PSA of greater than 20, a Gleason score of 8 or higher, and they have to have a BRCA1 or BRCA2 mutation. These patients will then undergo chemotherapy with carboplatin in addition to androgen deprivation therapy, and then they will have radical prostatectomy as a way to define whether there is a pathological tissue response, which is the primary end point for this particular trial.
What are the potential implications of this study?
This is a phase 2 study. So, this is basically designed to look at activity in the complete and partial response rates to chemotherapy. If this does show some significant activity, then this potentially could go into a phase 3 trial. As I mentioned earlier, we know that the BRCA1/BRCA2 patients tend to have a poorer prognosis overall than the general patients with the wild-type phenotype. This may be a way of treating earlier stage aggressive prostate cancer with chemotherapy and selecting patients based upon their biological profiles.
This transcription has been edited for clarity.